Evidence map›Paper›PMID 32023326›Full record

Trial reportPLoS pathogens2020

Dynamics of HIV DNA reservoir seeding in a cohort of superinfected Kenyan women.

Mark D Pankau, Daniel B Reeves, Elias Harkins, Keshet Ronen, Walter Jaoko, Kishor Mandaliya, Susan M Graham, R Scott McClelland, Frederick A Matsen Iv, Joshua T Schiffer and 2 more

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 58 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Mark D PankauHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Daniel B ReevesVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.ORCID 0000-0001-5684-9538
Elias HarkinsDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Keshet RonenDepartment of Global Health, University of Washington, Seattle, WA, United States of America.ORCID 0000-0001-5625-4884
Walter JaokoDepartment of Medical Microbiology, University of Nairobi, Kenyatta National Hospital, Nairobi, Kenya.
Kishor MandaliyaCoast Provincial General Hospital, Women's Health Project, Mombasa, Kenya.
Susan M GrahamDepartment of Global Health, University of Washington, Seattle, WA, United States of America.ORCID 0000-0001-7847-8686
R Scott McClellandDepartment of Global Health, University of Washington, Seattle, WA, United States of America.
Frederick A Matsen IvDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.ORCID 0000-0003-0607-6025
Joshua T SchifferVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Julie OverbaughHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Dara A LehmanHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.ORCID 0000-0002-0372-0631
University of Washington · USFred Hutch Cancer Center · USUniversity of Nairobi · KE

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
Cell and Gene Therapy for HIV CureUM1AI126623 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI JEROME, KEITH R, KIEM, HANS-PETER · 2016 to 2020
$24.2M
EARLY INFECTION IN WOMEN EXPOSED MUCOSALLY TO HIV-1R37AI038518 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OVERBAUGH, JULIE M. · 1999 to 2019
$12.9M
Infant immune mechanisms of HIV reservoir size and decayR01HD094718 · NICHD · UNIVERSITY OF WASHINGTON · PI JOHN-STEWART, GRACE C., LEHMAN, DARA ANN · 2017 to 2021
$3.6M
Leveraing deep sequencing data to understand antibody maturationR01GM113246 · NIGMS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MATSEN, FREDERICK ALBERT · 2014 to 2018
$1.9M
Simulating persistence and elimination of the HIV reservoirK25AI155224 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI REEVES, DANIEL · 2020 to 2024
$581k
NCI NIH HHS P30 CA015704NIAID NIH HHS K25 AI155224NIAID NIH HHS P30 AI027757NIAID NIH HHS R37 AI038518NIAID NIH HHS UM1 AI126623NICHD NIH HHS R01 HD094718NIGMS NIH HHS R01 GM113246
6 · The paper itself

Abstract

A reservoir of HIV-infected cells that persists despite suppressive antiretroviral therapy (ART) is the source of viral rebound upon ART cessation and the major barrier to a cure. Understanding reservoir seeding dynamics will help identify the best timing for HIV cure strategies. Here we characterize reservoir seeding using longitudinal samples from before and after ART initiation in individuals who sequentially became infected with genetically distinct HIV variants (superinfected). We previously identified cases of superinfection in a cohort of Kenyan women, and the dates of both initial infection and superinfection were determined. Six women, superinfected 0.2-5.2 years after initial infection, were subsequently treated with ART 5.4-18.0 years after initial infection. We performed next-generation sequencing of HIV gag and env RNA from plasma collected during acute infection as well as every ~2 years thereafter until ART initiation, and of HIV DNA from PBMCs collected 0.9-4.8 years after viral suppression on ART. We assessed phylogenetic relationships between HIV DNA reservoir sequences and longitudinal plasma RNA sequences prior to ART, to determine proportions of initial and superinfecting variants in the reservoir. The proportions of initial and superinfection lineage variants present in the HIV DNA reservoir were most similar to the proportions present in HIV RNA immediately prior to ART initiation. Phylogenetic analysis confirmed that the majority of HIV DNA reservoir sequences had the smallest pairwise distance to RNA sequences from timepoints closest to ART initiation. Our data suggest that while reservoir cells are created throughout pre-ART infection, the majority of HIV-infected cells that persist during ART entered the reservoir near the time of ART initiation. We estimate the half-life of pre-ART DNA reservoir sequences to be ~25 months, which is shorter than estimated reservoir decay rates during suppressive ART, implying continual decay and reseeding of the reservoir up to the point of ART initiation.

Indexed as

DNA, Viralenv Gene Products, Human Immunodeficiency Virusgag Gene Products, Human Immunodeficiency VirusHIV-1HIV InfectionsPhylogenyAdultFemaleFollow-Up StudiesHigh-Throughput Nucleotide SequencingHumansKenyaDNA, Viralenv Gene Products, Human Immunodeficiency Virusgag Gene Products, Human Immunodeficiency Virus

Identifiers

PMID32023326
PMCPMC7028291
OpenAlexW3004870049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.